journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28079594/impact-of-concurrent-medication-use-on-pancreatic-cancer-survival-seer-medicare-analysis
#1
Muhammad S Beg, Arjun Gupta, David Sher, Sadia Ali, Saad Khan, Ang Gao, Tyler Stewart, Chul Ahn, Jarett Berry, Eric M Mortensen
OBJECTIVES: Preclinical studies have suggested that non-antineoplastic medication use may impact pancreatic cancer biology. We examined the association of several medication classes on pancreatic cancer survival in a large medical claims database. MATERIALS AND METHODS: Histologically confirmed pancreatic adenocarcinoma diagnosed between 2006 and 2009 were analyzed from the Surveillance, Epidemiology, and End Results-Medicare database with available part D data...
January 10, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28059930/acr-appropriateness-criteria-locally-advanced-high-risk-prostate-cancer
#2
Patrick W McLaughlin, Adam L Liss, Paul L Nguyen, Dean G Assimos, Anthony V D'Amico, Alexander R Gottschalk, Gary S Gustafson, Sameer R Keole, Stanley L Liauw, Shane Lloyd, Benjamin Movsas, Bradley R Prestidge, Timothy N Showalter, Al V Taira, Neha Vapiwala, Brian J Davis
PURPOSE: To present the most updated American College of Radiology consensus guidelines formed from an expert panel on treatment of locally advanced, high-risk prostate cancer METHODS:: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios...
January 4, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28059929/hepatic-progression-free-and-overall-survival-after-regional-therapy-to-the-liver-for-metastatic-melanoma
#3
Andrea M Abbott, Matthew P Doepker, Youngchul Kim, Matthew C Perez, Cassandra Gandle, Kerry L Thomas, Junsung Choi, Ravi Shridhar, Jonathan S Zager
OBJECTIVES: Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) were evaluated. MATERIALS AND METHODS: A retrospective review of patients with liver metastases from cutaneous or uveal melanoma treated with yttrium-90 (Y90), chemoembolization (CE), or percutaneous hepatic perfusion (PHP) was conducted. RESULTS: Thirty patients (6 Y90, 10 PHP, 12 CE, 1 PHP then Y90, 1 CE then PHP) were included...
January 4, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28009597/a-review-of-treatment-for-breast-cancer-related-lymphedema-paradigms-for-clinical-practice
#4
Timothy D Smile, Rahul Tendulkar, Graham Schwarz, Douglas Arthur, Stephen Grobmyer, Stephanie Valente, Frank Vicini, Chirag Shah
OBJECTIVES: Breast cancer-related lymphedema (BCRL) represents a major complication of breast cancer treatment, impacting the quality of life for breast cancer survivors that develop it. The purpose of this review is to evaluate the literature surrounding BCRL treatment modalities to guide clinicians regarding risk-stratified treatment options. METHODS: A review of studies over a 10-year period (January 2006 to February 2016) was performed. Noninvasive strategies evaluated included compression therapy, manual lymphatic drainage, and complex decongestive therapy (CDT)...
December 22, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27906723/safety-and-outcome-measures-of-first-in-human-intraperitoneal-%C3%AE-radioimmunotherapy-with-212pb-tcmc-trastuzumab
#5
Ruby F Meredith, Julien J Torgue, Tania A Rozgaja, Eileen P Banaga, Patty W Bunch, Ronald D Alvarez, J Michael Straughn, Michael C Dobelbower, Andrew M Lowy
PURPOSE: One-year monitoring of patients receiving intraperitoneal (IP) Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS: Eighteen patients with relapsed intra-abdominal human epidermal growth factor receptor-2 expressing peritoneal metastases were treated with a single IP infusion of Pb-TCMC-trastuzumab, delivered <4 h after 4 mg/kg IV trastuzumab. Seven tumor markers were studied for correlation with outcome...
November 30, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27906722/location-and-grade-of-prostate-cancer-diagnosed-by-transperineal-template-guided-mapping-biopsy-after-negative-transrectal-ultrasound-guided-biopsy
#6
Nathan Bittner, Gregory Merrick, Al Taira, Abbey Bennett, Amy Schattel, Wayne Butler, Robert Galbreath, Edward Adamovich
OBJECTIVES: To determine the location and grade of prostate cancer diagnosed by transperineal template-guided mapping (TTMB) after negative transrectal ultrasound-guided (TRUS) biopsy. MATERIALS AND METHODS: This analysis consisted of 1118 consecutive patients who underwent TTMB from January 2005 to August 2015. Eight hundred thirty-five underwent TTMB after at least 1 negative TRUS biopsy and 283 underwent TTMB as the first biopsy procedure. The study population was divided into cohorts based on the number of prior TRUS biopsy sessions (0, 1, 2, and ≥3)...
November 30, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27893471/an-oncologist-s-perspective-on-the-affordable-care-act
#7
Chirag Shah, Shahed N Badiyan, Katie Keith
No abstract text is available yet for this article.
November 23, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27893470/the-association-between-out-of-pocket-costs-and-adherence-to-adjuvant-endocrine-therapy-among-newly-diagnosed-breast-cancer-patients
#8
Albert J Farias, Ryan N Hansen, Steven B Zeliadt, India J Ornelas, Christopher I Li, Beti Thompson
OBJECTIVE: To determine how out-of-pocket costs for adjuvant endocrine therapy (AET) medication affects adherence among newly diagnosed breast cancer survivors with private health insurance who initiate therapy. MATERIALS AND METHODS: We examined medical and pharmacy claims for the 1-year period after initiating AET using the Truven Health Analytics MarketScan database. Adherence was defined as ≥80% proportion of days covered. Mean out-of-pocket costs for AET fill were measured as the sum of copayments, coinsurance, and deductibles and adjusted to 30-day amounts...
November 23, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27893469/a-review-of-the-surgical-management-of-extrathoracic-solitary-fibrous-tumors
#9
Babar Kayani, Aadhar Sharma, Mathew D Sewell, Johnson Platinum, Andre Olivier, Timothy W R Briggs, Deborah M Eastwood
OBJECTIVES: Extrathoracic solitary fibrous tumors (ESFTs) are rare low-to-intermediate grade spindle-cell neoplasms of pluripotent fibroblastic or myofibroblastic origin. This review explores prognostic factors in the management of ESFTs and provides guidance on optimal treatment regimens based on the current literature. PATIENTS AND METHODS: Electronic searches were performed using MEDLINE, Embase, and the Cochrane library to identify studies on prognostic factors in the management of ESFTs published between January 1970 and June 2016...
November 23, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27849650/programmed-cell-death-ligand-1-pd-l1-expression-in-anal-cancer
#10
Rangaswamy Govindarajan, Swetha Gujja, Eric R Siegel, Anu Batra, Anwaar Saeed, Keith Lai, Jennifer D James, Bradley J Fogel, Stephen Williamson
OBJECTIVE: To evaluate the expression of programmed cell death-ligand 1 (PD-L1) in anal cancer. PATIENTS AND METHODS: In a retrospective cohort analysis, subjects with squamous cell carcinoma of the anal canal were tested for PD-L1 expression, then followed for recurrence and survival. Crude recurrence rates (CRRs), crude mortality rates (CMRs), and crude event rates (CERs) were assessed for PD-L1-dependent differences using Poisson regression. All 3 types of crude rate were expressed as the number that occurred per hundred person-years (hPY) of follow-up...
November 15, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27849649/a-multicenter-phase-ii-study-of-gemcitabine-capecitabine-and-bevacizumab-for-locally-advanced-or-metastatic-biliary-tract-cancer
#11
Renuka V Iyer, Venkata K Pokuri, Adrienne Groman, Wen W Ma, Usha Malhotra, Dan M Iancu, Catherine Grande, Tanios B Saab
OBJECTIVES: Vascular endothelial growth factor overexpression, seen in 42% to 76% of biliary tract cancers (BTCs), correlates with poor survival. We explored the safety/efficacy and potential biomarkers for bevacizumab in combination with gemcitabine-capecitabine in advanced BTCs. PATIENTS AND METHODS: Inoperable stage III/IV BTC patients in our prospective study were given 1000 mg/m of gemcitabine (on days 1, 8), 650 mg/m of capecitabine (on days 1 to 14), and 15 mg/kg of bevacizumab (on day 1) in 21-day cycles...
November 15, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27841802/disparity-in-outcomes-for-adolescent-and-young-adult-patients-diagnosed-with-pediatric-solid-tumors-across-4-decades
#12
Ishita Chen, Dario Pasalic, Benjamin Fischer-Valuck, Haydar Frangoul, Todd DeWees, Eric T Shinohara, Stephanie M Perkins
OBJECTIVE: Cancer mortality is a leading cause of disease-related death in the adolescent and young adult (AYA) population. Compared with older and younger patients, AYA patients often experience worse cancer-specific outcomes. Here, we compare AYA and pediatric overall survival (OS) in the most common pediatric extracranial solid tumors. MATERIALS AND METHODS: Using the US Surveillance, Epidemiology, and End Results database, we studied patients (age, 0 to 39 y) diagnosed with Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and Wilms tumor...
November 10, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27819879/outcome-after-surgery-for-extremity-soft-tissue-sarcoma-in-patients-presenting-with-metastasis-at-diagnosis
#13
Chandra K Krishnan, Han-Soo Kim, Jong Woong Park, Ilkyu Han
OBJECTIVES: About 10% of patients present with metastasis at diagnosis in extremity soft tissue sarcoma (STS). Although the prognoses of these patients is generally poor, prolonged survival has been demonstrated in some patients. Thus, better prognostication is needed to guide decisions regarding adjuvant therapy and surveillance. This study sought to analyze the survival and to identify clinicopathologic factors associated with survival in extremity STS patients presenting with metastasis at diagnosis...
November 4, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27819878/prognostic-factors-treatment-and-outcomes-in-early-stage-invasive-papillary-breast-cancer-a-seer-investigation-of-less-aggressive-treatment-in-a-favorable-histology
#14
Mohamad H Fakhreddine, Waqar Haque, Awad Ahmed, Mary R Schwartz, Andrew M Farach, Arnold C Paulino, Elizabeth Bonefas, Darlene Miltenburg, Polly Niravath, E Brian Butler, Bin S Teh
OBJECTIVES: Invasive papillary breast cancer (IPBCA) represents 0.5% of invasive BCA, and is thought to carry a favorable prognosis. This population-based study reports on prognostic factors, treatment, and outcomes of early-stage IPBCA to explore whether there is any evidence to support less aggressive treatment. MATERIALS AND METHODS: IPBCA cases from 1990 to 2009 of the recent Surveillance, Epidemiology, and End Results were analyzed. Inclusion criteria included patients with stage T1-2, N0 IPBCA...
November 4, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27819877/benefit-of-radiotherapy-in-extraskeletal-myxoid-chondrosarcoma-a-propensity-score-weighted-population-based-analysis-of-the-seer-database
#15
Eric J Kemmerer, Elizabeth Gleeson, Jaganmohan Poli, Robert T Ownbey, Luther W Brady, Wilbur B Bowne
OBJECTIVES: Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignancy for which the role of radiotherapy is not well-defined. We examine the effect of external beam radiotherapy (EBRT) on cancer-specific survival (CSS) for patients with localized EMC, in a propensity score weighted, population-based analysis. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results database (1973 to 2012) was queried for cases of localized EMC arising from soft connective tissues of the trunk and extremities treated with surgery and/or EBRT...
November 4, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27819876/impact-of-postoperative-adjuvant-chemotherapy-following-long-course-chemoradiotherapy-in-stage-ii-rectal-cancer
#16
Jonathan M Loree, Hagen F Kennecke, Richard M Lee-Ying, Rachel A Goodwin, Erin D Powell, Patricia A Tang, Julie A Price Hiller, Michael M Vickers, Winson Y Cheung
OBJECTIVES: Use of adjuvant chemotherapy (AC) following neoadjuvant chemoradiation (nCRT) is controversial in rectal cancer (RC). We assessed a multi-institutional database to determine if there was benefit from AC for pathologic stage II RC patients and whether the addition of oxaliplatin to fluoropyrimidine (OXAC) therapy impacted outcomes. MATERIALS AND METHODS: We included patients who underwent nCRT and had pathologic stage II (ypT3/4 ypN0) tumors. Disease-free survival and overall survival were assessed...
November 4, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27819875/clinical-outcomes-after-lung-stereotactic-body-radiation-therapy-in-patients-with-or-without-a-prior-lung-resection
#17
Ying Hou, Gretchen Hermann, John H Lewis, Hugo J Aerts, Elizabeth H Baldini, Aileen B Chen, Yolonda L Colson, Fred L Hacker, Joseph H Killoran, David E Kozono, Matthew Wagar, Jon O Wee, Raymond H Mak
OBJECTIVES: Tumor control (TC), toxicity and survival, following stereotactic body radiation therapy (SBRT) were compared between patients with and without a prior lung resection (PLR). MATERIALS AND METHODS: The study is comprised of 130 patients with 141 peripheral tumors treated with SBRT at our institution from 2009 to 2013. Primary TC and lobar control (LC) were defined per RTOG 0236. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4...
November 4, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28106686/response-to-comments-by-drs-hamaoka-and-beyea-on-the-birth-of-the-illegitimate-linear-no-threshold-model-an-invalid-paradigm-for-estimating-risk-following-low-dose-radiation-exposure
#18
Jeffry A Siegel, Bill Sacks, Charles W Pennington, James S Welsh
No abstract text is available yet for this article.
February 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28106685/totally-implantable-venous-access-devices-a-review-of-complications-and-management-strategies
#19
Omidreza Tabatabaie, Gyulnara G Kasumova, Mariam F Eskander, Jonathan F Critchlow, Nicholas E Tawa, Jennifer F Tseng
OBJECTIVE: Totally implantable venous access devices (portacaths, or "ports"), are widely used for intermittent central venous access especially for cancer patients. Although ports have a superior safety margin compared with other long-term venous access devices, there are a number of complications associated with their use. METHODS: This is a narrative review. We searched PubMed and Google Scholar for articles about complications related to the use of portacaths...
February 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27643717/acr-appropriateness-criteria%C3%A2-hodgkin-lymphoma-favorable-prognosis-stage-i-and-ii
#20
Sughosh Dhakal, Ranjana Advani, Leslie K Ballas, Bouthaina S Dabaja, Christopher R Flowers, Chul S Ha, Bradford S Hoppe, Nancy P Mendenhall, Monika L Metzger, John P Plastaras, Kenneth B Roberts, Ronald Shapiro, Sonali M Smith, Stephanie A Terezakis, Karen M Winkfield, Anas Younes, Louis S Constine
This topic addresses the treatment of newly diagnosed patients with favorable prognosis stage I and II Hodgkin lymphoma. In most cases, combined modality therapy (chemotherapy followed by involved site radiation therapy) constitutes the current standard of care. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios...
December 2016: American Journal of Clinical Oncology
journal
journal
28347
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"